| MYELOMA MINUTE | Up To The Minute News | 7.30.2020 |
|
 |
 |
| Get “Camp-y” with the IMF This Summer |
| This summer, the IMF staff has geared up to challenge ourselves. IMF staff member Karla Lemus promises to run 3 miles for every $25 she raises. Karla has already raised $935.00. Run Karla, run! Now, we are asking YOU if you will accept the same challenge. You can choose any virtual camp challenge you’d like. For example, maybe for every $10 you raise for the IMF, you’ll commit to doing one push-up. Then, create your virtual fundraiser for the International Myeloma Foundation on Facebook. Use the #CAMPIMF hashtag in the title of your fundraiser so we can invite you to our official CAMP IMF Facebook Group. Visit the IMF Facebook page now to learn more! |
|
|
 |
| Register for the Next IMF Patient & Family Webinar |
The next IMF Patient & Family Webinar is scheduled for Saturday, August 15, at 1:00 p.m. PT /
4:00 p.m. ET. This FREE two-hour webinar features a panel discussion about the latest treatments for and management of myeloma led by IMF Chairman Dr. Brian G.M. Durie. Panelists include Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen), Dr. Thomas Martin of the University of California San Francisco (UCSF) Health, and patient advocate Jack Aiello. |
|
|
 |
| Listen Now to “A Day in the Life” Podcast with Chrissy DeGennaro |
| In this podcast, you’ll hear 14-year myeloma survivor Chrissy DeGennaro share, “I want people to know that all these things are possible. Miracles happen. There may not be a cure, but the longer we stay alive, the faster science catches up. There’s so much hope right now that I want people to know that you can live with cancer. You can live with an incurable cancer. I’ve been doing it for over 14 years.” For your dose of weekly inspiration, listen to the full podcast now. |
|
|
 |
| And This Too Shall Pass…. |
| Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself sipping a tropical beverage next to a private pool, just minutes from the Hawaiian coastline. |
|
|
 |
| Learn More About Recently Approved Sarclisa and the Phase III IKEMA Trial |
| The IKEMA trial was a phase III study of patients with relapsed refractory multiple myeloma who had undergone 1-3 prior lines of therapy. It compared the combination of Sarclisa (isatuximab), Kyprolis (carfilzomib), and dexamethasone (Isa-Kd) to the combination of Kyprolis and dexamethasone (Kd). In this video, IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope — Phoenix) explains the methods, results, and conclusion of an interim analysis of the IKEMA study. |
|
|
 |
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
This Week’s Question:
How does mass spectrometry compare to traditional myeloma-protein testing methods? |
|
|
| |
|
|
| |
We Thank Our Sponsors:
|
| Amgen; Bristol-Myers Squibb; Genentech; GSK; Oncopeptides, Inc.; Sanofi-Genzyme; and Takeda Oncology |
| We also thank individuals like you for your continued support! |
|
|
| Join the conversation at The International Myeloma Foundation |
 Facebook: /Myeloma |  Twitter @IMFMyeloma |  Instagram @IMFmyeloma
www.myeloma.org |
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
1-800-452-2873 |
We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Privacy Policy |
| View as web page |
